中国生物制药：正大天晴药业安奈克替尼获批上市81.08%客观缓解率

和讯网04-30

【港股龙头药企中国生物制药下属正大天晴药业集团1类创新药富马酸安奈克替尼胶囊获国家药监局批准上市，为国内首个用于ROS1阳性非小细胞肺癌的靶向药。】中国生物制药宣布，其子公司正大天晴药业集团研发的富马酸安奈克替尼胶囊（TQ-B3101，安柏尼）获得国家药品监督管理局的批准，标志着国产创新药在非小细胞肺癌治疗领域取得重大突破。据悉，肺癌是中国发病率和死亡率最高的癌症类型，非小细胞肺癌占其80%至...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2431497321?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-30 19:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2431497321","market":"hk","top_or_hot":-1,"title":"中国生物制药：正大天晴药业安奈克替尼获批 上市81.08%客观缓解率","media":"和讯网","content":"<div>\n<p>【港股龙头药企中国生物制药下属正大天晴药业集团1类创新药富马酸安奈克替尼胶囊获国家药监局批准上市，为国内首个用于ROS1阳性非小细胞肺癌的靶向药。】 中国生物制药宣布，其子公司正大天晴药业集团研发的富马酸安奈克替尼胶囊（TQ-B3101，安柏尼）获得国家药品监督管理局的批准，标志着国产创新药在非小细胞肺癌治疗领域取得重大突破。据悉，肺癌是中国发病率和死亡率最高的癌症类型，非小细胞肺癌占其80%至...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021543887c40d3e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国生物制药：正大天晴药业安奈克替尼获批 上市81.08%客观缓解率</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国生物制药：正大天晴药业安奈克替尼获批 上市81.08%客观缓解率\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-30 19:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021543887c40d3e&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【港股龙头药企中国生物制药下属正大天晴药业集团1类创新药富马酸安奈克替尼胶囊获国家药监局批准上市，为国内首个用于ROS1阳性非小细胞肺癌的靶向药。】 中国生物制药宣布，其子公司正大天晴药业集团研发的富马酸安奈克替尼胶囊（TQ-B3101，安柏尼）获得国家药品监督管理局的批准，标志着国产创新药在非小细胞肺癌治疗领域取得重大突破。据悉，肺癌是中国发病率和死亡率最高的癌症类型，非小细胞肺癌占其80%至...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021543887c40d3e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021543887c40d3e&s=b","article_id":"2431497321","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021543887c40d3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2431497321","pubTimestamp":1714476120,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"【港股龙头药企中国生物制药下属正大天晴药业集团1类创新药富马酸安奈克替尼胶囊获国家药监局批准上市，为国内首个用于ROS1阳性非小细胞肺癌的靶向药。】 中国生物制药宣布，其子公司正大天晴药业集团研发的富马酸安奈克替尼胶囊获得国家药品监督管理局的批准，标志着国产创新药在非小细胞肺癌治疗领域取得重大突破。据悉，肺癌是中国发病率和死亡率最高的癌症类型，非小细胞肺癌占其80%至85%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","01177":"中国生物制药","BK1589":"北水核心资产","BK1191":"制药"},"translate_title":"China Biopharmaceuticals: Chia Tai Tianqing Pharmaceutical's anecotinib was approved for marketing with an objective response rate of 81.08%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"【港股龙头药企中国生物制药下属正大天晴药业集团1类创新药富马酸安奈克替尼胶囊获国家药监局批准上市，为国内首个用于ROS1阳性非小细胞肺癌的靶向药。】 中国生物制药宣布，其子公司正大天晴药业集团研发的富马酸安奈克替尼胶囊（TQ-B3101，安柏尼）获得国家药品监督管理局的批准，标志着国产创新药在非小细胞肺癌治疗领域取得重大突破。据悉，肺癌是中国发病率和死亡率最高的癌症类型，非小细胞肺癌占其80%至85%。 安奈克替尼胶囊是正大天晴自主研发的创新药，针对ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者。研究发现，ROS1基因融合是非小细胞肺癌的关键驱动基因，尤其在东亚人群中，其发生率高达2%至3%。 中国生物制药首席执行长、正大天晴药业集团董事长谢承润指出：“公司以临床价值为核心，针对中国庞大的肺癌患者群体，持续在该领域深耕。安奈克替尼胶囊的上市，将为ROS1阳性非小细胞肺癌患者提供更多选择，同时推动公司肿瘤领域产品线的发展，造福更多患者。” 临床研究显示，安奈克替尼单药治疗ROS1阳性非小细胞肺癌的客观缓解率（ORR）高达81.08%，缓解持续时间（DOR）中位数达20.3个月。对于存在脑转移的患者，颅内客观缓解率（CNS-ORR）、中位颅内缓解持续时间（CNS-mDOR）和中位颅内疾病进展时间（CNS-mTTP）分别为72.73%、9.36个月和17.25个月。 根据国家癌症中心数据，肺癌在中国恶性肿瘤中的发病和死亡人数均居首位。目前，国内市场上已有的ROS1抑制剂均为进口药物。头豹研究院预计，到2024年，中国非小细胞肺癌新发病人数将达到88.4万人，市场规模将达到822.4亿元，显示中国在ROS1阳性非小细胞肺癌治疗领域存在巨大的临床需求。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431497321"}

中国生物制药：正大天晴药业安奈克替尼获批 上市81.08%客观缓解率

精彩评论

中国生物制药：正大天晴药业安奈克替尼获批上市81.08%客观缓解率